ArticleScientific reports2026
Hsa_circ_0002111 implicates KTC-1 cell motility and modulates migration and invasion via miR-432-5p/CDKN2B axis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hsa_circ_0002111 is highly expressed in papillary thyroid carcinoma (PTC). We therefore investigated its role and underlying mechanism in promoting PTC progression. Q-RT-PCR, dual-luciferase reporter assays, AGO2-RIP, CCK-8, colony formation, wound healing, and Transwell assays were employed to dissect the circRNA/miRNA/mRNA axis interactions and their functional phenotypes. Results showed that silencing hsa_circ_0002111 significantly inhibited the viability, migration, and invasion of KTC-1 cells. Mechanistic studies demonstrated that hsa_circ_0002111 acted as a sponge for miR-432-5p, which in turn targeted the 3'UTR of CDKN2B and suppressed its expression. Functional assays revealed that either hsa_circ_0002111 knockdown or miR-432-5p overexpression inhibited migration and invasion, whereas inhibition of miR-432-5p reversed these cellular processes. Consistently, siRNA-mediated knockdown of CDKN2B phenocopied the motility defects observed upon hsa_circ_0002111 silencing, suggesting that CDKN2B is a functionally relevant downstream effector. Thus, the hsa_circ_0002111/miR-432-5p/CDKN2B axis is implicated in papillary thyroid carcinoma progression. These findings revealed a novel regulatory mechanism of hsa_circ_0002111 in KTC-1 cells and suggest its potential as a therapeutic target, offering new insights for future clinical applications and research directions in thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.